As research continues, those involved say this would be a game changer, especially for patients with very limited options.

Emil Kraepelin formulated the initial nosology of Alzheimer's disease in the first decade of the 20th century. Nowadays, clinical and pathological presentations (including those associated with ...

A study by the (UPV/EHU) demonstrates that the drug WIN55,212-2 protects the brain and reverses early cognitive damage caused ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without yet causing any symptoms. The first symptoms are usually mild. People may ...

Even though a person with dementia may end up sleeping more than a typical person of ... and tends to happen from the earliest stages of the disease onwards. This can be exhausting and often leaves ...

15, 2025 — Regular aerobic exercise could significantly reduce disease ... to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug ...

Alzheimer’s disease could ... Alzheimer’s disease, they would then benefit from taking new drugs that are on the market and specifically designed to treat early-stage disease.

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

However, the length of the region between the end of the protein production ... Maybe if the patient is at a late stage of Alzheimer’s disease, unfortunately, it would be difficult to reverse ...

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease ... could be released at the end of this year or early 2026 ...